LIXTE Biotechnology Announced Publication Of Data In EMBO Reports Showing LB-100 Increases Recognition Of Colon Cancer Cells By Immune System
Portfolio Pulse from Benzinga Newsdesk
LIXTE Biotechnology announced that their drug LB-100 has shown promising results in increasing the recognition of colon cancer cells by the immune system. The data, published in EMBO Reports, indicates that LB-100 generates neo-antigens in cancer cells by disrupting RNA splicing, which are then presented to the immune system.
June 06, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LIXTE Biotechnology's LB-100 has shown potential in increasing the immune system's recognition of colon cancer cells by generating neo-antigens. This could lead to increased interest and investment in the company.
The publication of positive data in a reputable journal like EMBO Reports is likely to boost investor confidence in LIXTE Biotechnology. The potential of LB-100 to enhance immune recognition of cancer cells could attract more interest and investment in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100